Answers are grounded in this paper and cite their sources.
BACKGROUND AND OBJECTIVES: Overexpression of the cytoskeleton-modulating kinase ROCK1 has been associated with unfavorable outcome in many cancers, but its impact in prostate cancer is largely unknown. RESULTS: G fusion, genomic deletions of the PTEN tumor suppressor, as well as recurrent deletions at chromosomes 3p, 5q, 6q. Strong ROCK1 staining was found in 3% of AR-negative, but in 27% of strongly AR positive cancers, in 13% of ERG-negative but in 25% of ERG positive cancers, and in 12% of PTEN normal but in 26% of PTEN deleted cancers. CONCLUSIONS: This study identifies ROCK1 expression associated with prognosis in prostate cancer. METHODS: We tested ROCK1 expression in 12 427 prostate cancer specimens and followed PSA recurrence after prostatectomy.
No takes yet. Share an insight, caveat, or question.
Steurer et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: